|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Basin development and tectonic history of the Llanos Basin,Eastern Cordillera,and Middle Magdalena Valley,Colombia显示文摘 | M A Cooper F T Addison R Alvarez | 1995 | AAPG Bulletin1995，79，10： | 1 |
| 2 | Organic contaminants in the northwest Atlantic atmosphere at Sable Island, Nova Scotia, 1988-1989显示文摘 | Bidleman T F Cotham W E Addison R F | 1992 | Chemosphere1992，24，9： | 1 |
| 3 | Standard pulse oximeters can be used to monitor respiratory rate 显示文摘 | Leonard P Beattie T F Addison P S | 2003 | Emergency medicine journal2003，20，6： | 1 |
| 4 | Basin development and tectonic history of the Llanos basin,eastern Cordillera,and middle Magdalena valley,Colombia显示文摘 | Cooper M A Addison F T Alvarez R | 1995 | AAPG Bulletin1995，79，10： | 1 |
| 5 | Trends in Organochlorine residue concentrations in tinged seal (phoca hispida) from Holman, Northwest Territories, 1972-91 显示文摘 | ADDISON R F SMITH T G | 1998 | Arctic1998，51，3： | 1 |
| 6 | Basin development and tectonic history of the Llanos Basin, Eastern Cordillera, and Middle Magdalena Valley, Colombia 显示文摘 | Cooper M A Addison F T Alvarez R | 1995 | AAPG Bulletin1995，79，： | 1 |
| 7 | Hepatitis C virus replication in mice with chimeric human livers 显示文摘 | Mercer D F Schiller D E Elliott J F Douglas D N Hao C Rinfret A Addison W R Fischer K P Churchill T A Lakey J R Tyrrell D L Kneteman N M | 2001 | Nat Med2001，，08： | 1 |
| 8 | Basin development and tectonic history of the Llanos Basin,Eastern Cordillera,and Middle Magdalena Valley,Colombia显示文摘 | Cooper M A Addison F T Alvarez A | 1995 | AAPG Bulletin1995，79，10： | 1 |
| 9 | Basin Development and Tectonic History of the Llanos Basin,Eastern Cordillera,and Middle Magdalena Valley,Colombia显示文摘 | COOPER M A ADDISON F T ALVAREZ R | | 0，，10： | 1 |
| 10 | Basin development and tectonic history of the Llanos Basin,eastern Cordillera and middle Magdalena valley,Colombia显示文摘 | Cooper M A Addison F T Alvarez R | 1995 | AAPG Bulletin1995，79，10： | 1 |
| 11 | 依鲁替尼治疗后的高血压和心血管事件显示文摘依鲁替尼对B细胞恶性肿瘤有显著疗效。然而,依鲁替尼与潜在的限制性心脏毒性有关,包括新出现的严重高血压。使用依鲁替尼对高血压的发病率、严重程度的影响尚不清楚。研究者在2009-2016年间连续使用依鲁替尼治疗B细胞恶性肿瘤的562例患者中,评估了新发高血压或高血压进展的发生率(收缩压临界值为130mm Hg,1mm Hg=0.133kPa)。所观察到的高血压发生率与通过Framingham心脏预测的高血压发生率进行比较。 | 刘青(译) 叶鹏(摘、审校) Dickerson T Wiczer T Waller A Philippon J Porter K Haddad D Guha A Rogers KA Bhatt S Byrd JC Woyach JA Awan F Addison D | 2020 | 中华高血压杂志2020，28，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员